期刊
BIOLOGICAL PSYCHIATRY
卷 74, 期 5, 页码 329-332出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.biopsych.2013.04.011
关键词
Alzheimer's disease; amyloid beta; antibodies; cellular immunity; cerebral amyloid angiopathy; immunotherapy
资金
- Institut de Neurosciences translation-nelles de Paris (IHU-A-ICM)
- Novartis
- Lundbeck
Results of Phase III studies involving a large number of Alzheimer's disease (AD) patients treated by passive immunotherapy with humanized anti-amyloid beta monoclonal antibodies have recently been released. These approaches failed to show a significant clinical benefit in patients with mild to moderate AD. The most considered explanation is that the patients have been treated too late. Whereas targeting patients at asymptomatic stages of the disease is a critical step in the goal of improving the efficacy of such antibody-based strategies, several other important factors should be considered in the development and clinical evaluation of anti-amyloid beta immunotherapies, including the as yet poorly understood relationship of AD with the immune system and the importance of cerebral amyloid angiopathy. Better understanding the role of immune responses in AD and their impact on immunotherapy appears essential in the design of alternative or combinatorial immunotherapy approaches in AD, which may imply effectors other than antibodies and even additional antigenic targets.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据